Status:

COMPLETED

Synergy Between morpHOlogical and inflammatoRy Evaluation in Predicting Long-term Coronary Plaque Progression

Lead Sponsor:

University of Bologna

Collaborating Sponsors:

University of Cambridge

Centro per la Lotta Contro l'Infarto - Fondazione Onlus

Conditions:

Acute Coronary Syndrome

Atherosclerosis

Eligibility:

All Genders

50+ years

Phase:

NA

Brief Summary

Data from human autopsy studies have showed that thrombosis of a ruptured plaque with a large necrotic core, inflammatory cells and a thin fibrous cap, the so-called thin cap fibroatheroma (TCFA), rep...

Detailed Description

ACS are the leading cause of mortality and morbidity in the western world. Despite recommended therapies, after experiencing an ACS episode patients still have an increased cardiovascular risk during ...

Eligibility Criteria

Inclusion

  • Male or female participants \> 50 years old
  • Able to give written, informed consent and to lie flat
  • Presentation of ACS within \~2 weeks
  • At least 1 intermediate (30-80% diameter stenosis) non-culprit coronary artery lesion on angiography, managed medically as clinically indicated (i.e.: negative FFR/iFR)

Exclusion

  • Women of child bearing potential not using adequate contraception
  • Contrast allergy or contrast-nephropathy
  • Uncontrolled atrial fibrillation
  • Chronic kidney disease (eGFR \<30 l/min/1.73m2)
  • Uncontrolled chronic inflammatory disorder
  • History of recent malignancy deemed relevant to the study by the investigator
  • Current use of systemic corticosteroids
  • Previous coronary artery bypass grafting surgery (CABG) or percutaneous coronary intervention (PCI) before the index event
  • Contraindication to coronary angiography
  • Requires CABG or staged non-culprit artery PCI
  • Coronary vessels that could not be adequately imaged
  • Severe valvular heart disease
  • Any medical condition, in the opinion of the investigator, that prevents the participant from lying flat during scanning, or from participating in the study.

Key Trial Info

Start Date :

June 21 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 21 2024

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT05436977

Start Date

June 21 2021

End Date

June 21 2024

Last Update

May 20 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Bologna IRCCS Policlinico di St. Orsola

Bologna, Italy